Fentiazac

General information

Fentiazac, a thiazoleacetic acid derivative, has the same adverse reactions profile as other NSAIDs. Adverse reactions in as many as 56% of patients (5–56%), are even more frequent than with phenylbutazone [ ].

In 40 patients with rheumatoid arthritis enrolled in a double-blind trial of fentiazac 400 mg/day or sulindac 200 mg/day for 3 months, adverse reactions were reported in three patients taking fentiazac (rashes, headaches, epigastric pain) [ ].